AXIOS February 7, 2024
Biden administration officials this week pushed executives from leading pharmacy chains to make sure frontline staff are providing patients with accurate information about costs of the COVID-19 treatment Paxlovid, officials told Axios first.
Why it matters: Uptake of the Pfizer antiviral has remained stubbornly low since it transitioned to the commercial market in the fall, in part because of patients sometimes being charged up to the full list price of $1,400.
Details: Officials tracking Paxlovid’s commercial rollout have closely monitored anecdotal reports in the past few weeks of patients being charged high co-pays for Paxlovid at pharmacy counters rather than being directed to Pfizer-operated patient assistance programs.
- Health and Human Services Secretary Xavier Becerra “made it clear that no...
Today's Sponsors
Today's Sponsor